Translating current biomedical therapies for long duration, deep space missions

Sonia Iosim, Matthew MacKay, Craig Westover and Christopher E. Mason

1Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY 10021, USA, 2The HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY 10021, USA, 3The Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10021, USA, and 4The WorldQuant Initiative for Quantitative Prediction, Weill Cornell Medicine, New York, NY 10021, USA

Abstract

It is been shown that spaceflight-induced molecular, cellular, and physiologic changes cause alterations across many modalities of the human body, including cardiovascular, musculoskeletal, hematological, immunological, ocular, and neurological systems. The Twin Study, a multi-year, multi-omic study of human response to spaceflight, provided detailed and comprehensive molecular and cellular maps of the human response to radiation, microgravity, isolation, and stress. These rich data identified epigenetic, gene expression, inflammatory, and metabolic responses to spaceflight, facilitating a better biomedical roadmap of features that should be monitored and safeguarded in upcoming missions. Further, by exploring new developments in pre-clinical models and clinical trials, we can begin to design potential cellular interventions for exploration-class missions to Mars and potentially farther. This paper will discuss the overall risks astronauts face during spaceflight, what is currently known about human response to these risks, what pharmaceutical interventions exist for use in space, and which tools of precision medicine and cellular engineering could be applied to aerospace and astronaut medicine.

Key words: NASA; spaceflight; International Space Station; NASA Twin Study; multi-scale omics

Introduction

Previous studies have demonstrated numerous human spaceflight-induced complications, such as cardiovascular alterations, bone and muscle loss, ocular dysfunction, risk of malignancy, hematological issues, and behavioral changes. In the past decade, omics studies have given us a closer look at cellular processes that indicate genetic, transcriptional, translational, inflammatory, and metabolic responses to the space environment. More recently, the NASA Twin Study created a unique, multi-omics analysis of a pair of monozygotic twins that examined spaceflight-related changes on a more...
comprehensive level than has ever been done before. This study used recent technological advances to create extensive molecular maps of the cellular and genetic changes that occur in astronauts, including alterations in DNA, RNA, proteins, lipids, metabolites, and the microbiome. This has also given us new insight into how radiation, microgravity, isolation, and stress affect the body, as well as new tools for monitoring changes in astronaut health.

Building on this work, many space agencies and research groups are now focusing on leveraging the methods of “precision medicine” to increase the safety of astronaut missions and improve long-term astronaut health and safety. Further advances have been made on Earth for cellular therapeutics, which are continuously changing the paradigm of treatment for many diseases—especially in cancer. By taking examples from regenerative medicine and immune-oncology, we can begin to design cellular therapeutics that may further protect astronauts and allow for missions of longer duration.

According to NASA, there are five main hazards of human spaceflight: radiation, gravity, distance (from Earth), hostile enclosed environments, and isolation. Although it may be challenging to dissociate these hazards from one another when studying an astronaut’s response to spaceflight, all hazards must be addressed and appropriately assessed before each mission. As an example, the distance from Earth (or a future-base) forces astronauts to be more self-reliant because of the increased time delay of communications as well as the finite supply of non-replenishable goods. Further, both isolation and hostile environments play major roles in the success of a mission and must be carefully planned for with specific astronauts in mind.

In this paper, we discuss the responses of the human body to spaceflight, with an emphasis on specific changes caused by radiation and microgravity. We discuss new findings from the Twin Study, including potential risks for future astronauts during longer, or farther, missions from Earth. We cover pharmaceuticals in space as well as current therapies, clinical trials, and medical paradigms on Earth, which may be the building blocks for future astronaut medicine. This includes translation of cellular therapies, genetically engineered therapies, next-generation sequencing, multi-omic analyses, customized antibiotics, and precise nutritional regimes based on an astronaut’s microbiome.

**Spaceflight hazard: radiation**

Radiation is a clear spaceflight risk, particularly the strong galactic cosmic rays (GCRs) that are mostly protected against by the Earth’s atmosphere and magnetosphere. Radiation damages DNA, RNA, proteins, and lipids, and increases overall oxidative stress within cells. Although the health effects of acute radiation exposure have been comprehensively studied, much less is known about the effects of chronic exposure for astronauts undertaking long missions outside Earth’s orbit. Also, it is important to note that being exposed to a large dose of radiation within a short time-frame will be more dangerous than the same dosage over a longer duration, primarily because of cellular turnover. To put radiation exposure into the context of spaceflight, we aggregated multiple sources to visualize relative radiation exposure from medical tests, time on a celestial body within our solar system, the duration of select missions, and finally the current career-long occupational maximum radiation exposure for astronauts (Fig. 1).

Each type of exposure can carry very different degrees of risk. As an example, a year on Earth will expose an average human to 3 milliSieverts (3 mSv), whereas the maximum whole-body occupational exposure for a year on a job for radiation workers in the United States is 50 mSv. Notably, 1 year on the surface of the Moon would likely expose an astronaut to 100–350 mSv, depending on solar conditions. When traveling to other celestial bodies, radiation will be a primary risk factor. Some celestial bodies, such as Titan, would expose astronauts to lethal limits within a day (>-5,000 mSv), whereas other bodies would expose astronauts to less radiation than that to which humans are normally exposed (e.g., Venus). To put this in the context of an astronaut, one 30-month round trip mission to Mars (6-month trips each way with 18 months on the surface) would put a 25-year-old female at her career limit, whereas this same person could be on the Moon (approximately the same yearly radiation as Mars) for roughly 4 years. Simply put, the transit time is so much less to get to the Moon, that the risk is decreased. Further, a male, 55-year-old astronaut could have accomplished either of these missions four times before meeting his career limit.

The main concerns with radiation are pathological vascular changes, genetic mutations, immune dysfunction, and cancer.5–10 Epidemiological studies have suggested a latent relationship between radiation exposure and cardiovascular disease,6–9 as well as with clonal hematopoiesis,11 and physiologic studies in mice have shown long-lasting changes in cardiomyocyte gene expression and cellular signaling. The astronaut career limits are set based on a permissible career exposure limit of a 3% increased risk of exposure-induced death from cancer, estimated at a 95% confidence interval using a system developed by the National Council on Radiation Protection and Measurements that accounts for individual differences in risk (e.g., age, gender, smoking history).3 However, a study of former astronauts found no significant correlation between space radiation dose and cardiovascular or cancer-associated mortality.7 The study recognizes its small sample size and statistical limitations, but it points out that much remains to be learned about long-term outcomes of space radiation exposure and the actual extent of the threat that it poses.
Nonetheless, leukemias are known to be among the most common radiation-induced cancers and pose a particular risk because they can develop relatively rapidly. A study showed that simulated solar energetic particle and GCR radiation led to DNA damage and altered differential potential of human hematopoietic stem cells, indicating a risk of malignancy and signs of immune dysfunction. Furthermore, it showed a distinct difference in gene expression not only in irradiated versus control cells, but also a difference between cells exposed to different types of radiation. Numerous other studies found changes in regulation of the immune system, altered interactions between innate and adaptive components of the immune system.
and significant dampening of lymphocyte response to stimuli.15 These features may also alter the risk of clonal hematopoiesis and the emergence of mutated alleles.16,17 Additionally, it was found that latent herpes virus was reactivated in subjects during a 6-month spaceflight.14

**Spaceflight hazard: gravity**

There have been many studies on the health effects from microgravity, most significantly effects on the cardiovascular and musculoskeletal systems. It is known that a headward shift of fluid occurs, causing maladaptive changes that put stress on blood vessels and the heart. Furthermore, other studies have shown that the resulting increased cranial pressure may induce optic disc edema that can lead to choroidal folds, a pathology that has been termed “spaceflight-associated neuro-ocular syndrome”, or SANS. The decreased gravitational load also leads to muscle atrophy and bone loss. In the years leading up to the Twin Study, studies focused on the molecular changes that occur because of microgravity. Researchers have been aiming to uncover pathologic mechanisms and unanticipated effects using off-target profiling. For instance, microgravity and simulated microgravity experiments have shown elevations in myostatin (a protein that inhibits muscle growth),18 decrease in PGC-1α (peroxisome proliferator-activated receptor gamma coactivator-1 alpha), a regulator of mitochondrial proliferation,19,20 and increased physiological and cognitive sensitivity to carbon dioxide levels. Transcriptome studies found upregulation of the antibacterial response protein classes of actin and actin-related proteins, and of oxytocin- and serotonin-mediated pathways.

Microgravity simulations have shown that plasma levels of both coagulative and fibrinolytic proteins decrease, impacting the blood-clotting cascade, and they showed that a protein hormone biomarker of cardiovascular workload (NT pro-BNP) increases.21 Furthermore, these kinds of simulations have shown that microgravity induces cytoskeletal alterations that affect a wide range of cellular processes, including proliferation, migration, and signal transduction.22 Renal proteins serving as biomarkers of electrolyte regulation were altered, likely because of the fluid shifts that occur, overall decrease in plasma volume, and increased intake of salt additives. One study examining astronaut urinary proteome found that three proteins, glucosidase alpha acid (GAA), heparan sulfate proteoglycan (HSPG2), and alanyl aminopeptidase (ANPEP), do not return to baseline levels post-spaceflight, possibly correlating to changes in cytoskeletal reorganization, angiogenesis, extracellular matrix reorganization, and some features of hormone metabolism.5 Additional proteomic changes that have been detected include increased production of cytokines (and cortisol),23 changes in regulators of aerobic metabolism, and decrease in muscle and bone protein metabolism.16,21

**Human response to a year in space**

Previous work has been done to analyze how multifactorial hazards of spaceflight affect human functions, such as psychomotor and cognitive processing. Declines in movement speed, movement accuracy, internal time-keeping, and limb position sense have been identified. Changes in vestibular orientation cause “space motion sickness” in up to 70% of astronauts during the first week in orbit. There has also been evidence of difficulty with prefrontal functions, including decision-making, attention, concentration, and spatial working memory. Additionally, issues with mood, depression, anxiety, and irritability have been documented. Overall, there appears to be a negative impact on neurocognitive performance, likely because of a combination of psychological stress, change in sleep, physiological stress, and perhaps even the effects of radiation, although the majority of these studies were relatively short term.

Within the Twin Study, two identical twins were examined over 5 months before flight, 1 year when one twin was on the International Space Station (ISS), and another eight months post-flight. This study is the first of its kind to examine the effects of space at the molecular, cellular, physiological, and cognitive levels while tracking an identical, Earth-bound, twin at the same time. The Twin Study analyzed 18 different sample types (including different blood cell fractions) and 20 different analyses (ranging from cognitive tests to cytokine profiling or RNA-sequencing) across over 300 samples (including cell type fractions) (Table 1).10

There were several key findings suggestive of significant stress on the body, many confirming previous findings, and some that gave us new insight. Strikingly, telomere lengthening occurred, but the mechanism and the health consequences of this finding are not currently known. However, telomeres rapidly shortened upon return to Earth, and the amount of critically short telomeres actually increased after return to Earth. Telomere dysregulation may play a role in cell aging, cell death, and may be a determinant of cancer risk in astronauts. Chromosome translocations increased both during and after spaceflight, further contributing to risk of malignancy and indicating an ongoing process to repair the genome after spaceflight. Locus-specific epigenetic changes and transcriptional alterations showed enrichment in DNA repair pathways, further supporting this result.

Significant shifts also occurred in immune function pathways, indicating the presence of immune stress and inflammation. There has been concern about dampening of immune function, but a vaccination response experiment showed that T-cell response was adequately mounted (as measured by T-cell receptor repertoire, or TCR, diversity). Metabolic changes were also observed, including altered amino acid metabolism, increased pro-inflammatory lipids, increased lactic acid production, and decreased mitochondrial respiration.
| Flight time | Sample type         | Analysis                        |
|-------------|---------------------|---------------------------------|
| Pre-flight  | Blood (plasma)      | Biochemistry                    |
| In-flight   | Blood (plasma)      | Biochemistry                    |
| Post-flight | Blood (plasma)      | Biochemistry                    |
| Pre-flight  | Blood (plasma)      | Cytokine profiling              |
| In-flight   | Blood (plasma)      | Cytokine profiling              |
| Post-flight | Blood (plasma)      | Cytokine profiling              |
| Pre-flight  | Blood (plasma)      | Oxidative status                |
| In-flight   | Blood (plasma)      | Oxidative status                |
| Post-flight | Blood (plasma)      | Oxidative stress and inflammation|
| Pre-flight  | Blood (plasma)      | Oxidative stress and inflammation|
| In-flight   | Blood (plasma)      | Oxidative stress and inflammation|
| Pre-flight  | Blood (PBMCs)       | qRT-PCR (T:A)                   |
| In-flight   | Blood (PBMCs)       | qRT-PCR (T:A)                   |
| Post-flight | Blood (PBMCs)       | qRT-PCR (T:A)                   |
| Pre-flight  | Blood (CD19)        | RNA-seq                         |
| Pre-flight  | Blood (CD4)         | RNA-seq                         |
| Pre-flight  | Blood (CD8)         | RNA-seq                         |
| Pre-flight  | Blood (LD)          | RNA-seq                         |
| Pre-flight  | Blood (PBMCs)       | RNA-seq                         |
| In-flight   | Blood (CD19)        | RNA-seq                         |
| In-flight   | Blood (CD8)         | RNA-seq                         |
| In-flight   | Blood (LD)          | RNA-seq                         |
| Post-flight | Blood (CD19)        | RNA-seq                         |
| Post-flight | Blood (CD4)         | RNA-seq                         |
| Post-flight | Blood (CD8)         | RNA-seq                         |
| Post-flight | Blood (LD)          | RNA-seq                         |
| Pre-flight  | Blood (CD19)        | RNA-seq                         |
| In-flight   | Blood (CD4)         | TCR                             |
| In-flight   | Blood (CD8)         | TCR                             |
| Pre-flight  | Blood (PBMCs)       | TCR                             |
| In-flight   | Blood (CD4)         | TCR                             |
| In-flight   | Blood (CD8)         | TCR                             |
| In-flight   | Blood (LD)          | TCR                             |
| Post-flight | Blood (CD19)        | TCR                             |
| Pre-flight  | Blood (plasma)      | Targeted metabolomics           |
| In-flight   | Blood (plasma)      | Targeted metabolomics           |
| Post-flight | Blood (plasma)      | Targeted metabolomics           |
| Pre-flight  | Blood (CD4)         | TCR                             |
| Pre-flight  | Blood (CD8)         | TCR                             |
| Pre-flight  | Blood (LD)          | TCR                             |
| Pre-flight  | Blood (PBMCs)       | TCR                             |
| Pre-flight  | Blood (T-cells)     | Telo-FISH/dGH                   |
| In-flight   | Blood (T-cells)     | Telo-FISH/dGH                   |
| Post-flight | Blood (plasma)      | Untargeted metabolomics         |
| Pre-flight  | Blood (plasma)      | Untargeted metabolomics         |
| Post-flight | Blood (plasma)      | Untargeted proteomics           |
| Pre-flight  | Blood (plasma)      | Untargeted proteomics           |
| Pre-flight  | Blood (CD4)         | WGBS                            |
| Pre-flight  | Blood (CD8)         | WGBS                            |
| In-flight   | Blood (CD4)         | WGBS                            |
| In-flight   | Blood (CD8)         | WGBS                            |
| Post-flight | Blood (CD4)         | WGBS                            |
| Post-flight | Blood (CD8)         | WGBS                            |
| Pre-flight  | Blood (plasma)      | Body mass                       |
| In-flight   | Blood (plasma)      | Body mass                       |
| Post-flight | Blood (plasma)      | Body mass                       |
| Pre-flight  | Blood (CD19)        | qRT-PCR (T:A)                   |
| Pre-flight  | Blood (CD8)         | qRT-PCR (T:A)                   |
| Pre-flight  | Blood (LD)          | qRT-PCR (T:A)                   |
| Pre-flight  | Blood (CD19)        | qRT-PCR (T:A)                   |
| Post-flight | Blood (CD19)        | qRT-PCR (T:A)                   |
| Post-flight | Blood (CD8)         | qRT-PCR (T:A)                   |
| Post-flight | Blood (LD)          | qRT-PCR (T:A)                   |
| In-flight   | Blood (ambient return) (CD19) | qRT-PCR (T:A) |
| In-flight   | Blood (ambient return) (CD4) | qRT-PCR (T:A) |
| In-flight   | Blood (ambient return) (LD) | qRT-PCR (T:A) |
| In-flight   | Blood (ambient return) (PBMCs) | qRT-PCR (T:A) |
| In-flight   | Blood (ambient return) (CD8) | qRT-PCR (T:A) |

(Continued)
Microbiome alterations were noted, both in species richness and microbe functionality, but species diversity was not significantly affected. The implications of these changes are not yet known, but are unlikely to be severe.

Furthermore, proteomic data aligned with the well-known physiological changes that occur in the space environment. Changes occurred in fluid and blood pressure regulation proteins, vascular remodeling proteins, and insulin-binding proteins that play a role in body mass and muscular deconditioning. Signs of cardiovascular inflammation and carotid artery thickening were found, and it is not currently known if this alteration is reversible. There was also evidence of SANS, which was expected given results from previous astronauts.

As in previous studies, cognitive measures showed a general decrease in speed and accuracy, but with a couple of nuanced findings. Cognitive speed actually initially increased during early in-flight testing—the decline in function occurred most significantly during the 6-month post-flight period. Previous studies have indicated that stress and radiation may decrease synaptic density within the brain, and that radioactive nucleotides may cross the blood-brain barrier and play a role in decline. Additional work needs to be done to better understand the mechanisms behind the cognitive decline, and to clarify how exactly microgravity, physiological and psychological stress, and radiation target the brain.

An important insight gained from the Twin Study is a better recognition of temporality of changes that occur during long-term exposure to space conditions. Levels of risk and types of dysfunction change are based on the duration of the exposure. There seems to be a distinguishable difference between the differentially expressed genes during the first 6 months of the trip compared with the last 3 months of the trip. Significantly greater transcriptional changes occurred during the second half of the mission, starting at month 6. Also, the number of genes that were differentially expressed and regulated increased 7-fold in the last 6 months of the mission.

While many of these changes returned to baseline upon return to Earth, a subset of genes had altered expression that persisted into the 6-month post-flight period. This raised some concern that spaceflight may permanently alter the expression of several genes, but it is too early to know from just this study alone. Inflammation signatures also showed an interesting temporal pattern. Cytokine levels were subdivided into three categories: those that increased above their baseline following spaceflight, those that decreased below their baseline following spaceflight, and those that showed a rapid and drastic increase upon return from spaceflight but then returned to baseline levels. This may indicate that some immune and inflammatory processes stabilized after space exposure, whereas others are upregulated or downregulated for an extended period of time.

There are a few high-risk categories that require special attention, in terms of monitoring and potential intervention. Astronauts appear to be particularly vulnerable to cardiac disease, musculoskeletal dysfunction, and ocular remodeling so it would be important to track cardiovascular function, fluid shifts, measures in musculoskeletal decline, and changes in vision. Cognitive function is another critical category that requires ongoing testing and evaluation, which consists of pre- and post-flight interviews and targeted examinations. This includes tests such as Visual Object Learning, Abstract Matching, Line Orientation, Emotion Recognition, etc.

**Pharmaceuticals in space**

Mitigating the adverse effects on astronaut health has been difficult and mostly includes interventions such as exercise, nutrition, and some medications. According to a 2017 report from NASA, the ISS currently has a total of 107 medications included in the medical kits.35 The study of pharmacotherapy in space has been limited but is crucial to astronaut health for both current and future missions. The medications used during spaceflight have primarily been for symptomatic relief, such as sleeping difficulties, fatigue, motion sickness, gastrointestinal problems, congestion, but have also included anti-infectives, bisphosphonates (to mitigate bone loss), and vitamins.36,37 The changes that occur in blood flow, plasma and extravascular volumes, dehydration, vascular permeability, and slowed gastrointestinal transit time may alter drug absorption, distribution, and elimination.38,39 Additionally, increased homogeneity of pulmonary perfusion in space (resulting in greater diffusion capacity)36,37 and higher deposition of aerosols inhaled in microgravity38,39 may increase the effect of aerosolized medications and their toxicities (salbutamol and fluticasone are two types of inhalers available onboard the ISS).40 Alterations in pharmacokinetics from these fluid shifts and effects of microgravity have only been objectively evaluated in a few drugs. Acetaminophen has been determined to have some delay in absorption and scopolamine kinetics were indeterminate; thus far, no modifications have been made to the prescription of these drugs in space.33,41,42

Liver function is fundamental to processing many types of medications, and data suggest that hep-

---

**Table 1. Continue.**

| Flight time | Sample type | Analysis |
|-------------|-------------|----------|
| In-flight   | Blood (ambient return) (PBMCs) | qRT-PCR TRAP |
| In-flight   | Blood (ambient return) (CD4) | RNA-seq |
| In-flight   | Blood (ambient return) (CD8) | RNA-seq |
| In-flight   | Blood (ambient return) (T-cells) | Telo-FISH/dGH |
| In-flight   | Blood (ambient return) (CD4) | WGBS |
| In-flight   | Blood (ambient return) (CD8) | WGBS |

Flight time references when samples were collected compared to time on ISS. Sample type abbreviations: lymphocyte depleted (LD) cells and peripheral blood mononuclear cells (PBMCs). Analysis abbreviations: RNA-sequencing (RNA-seq), telomere fluorescence in situ hybridization (Telo-FISH), quantitative real-time polymerase chain reaction (qRT-PCR), whole-genome bisulfite sequencing (WGBS).
atic enzyme expression changes during prolonged spaceflight. These findings are based on antipyrine metabolism, which is a biomarker for the function of several key cytochrome p450 isoenzymes (however, no phenotypic data have yet been produced). The mechanisms causing these changes are currently unknown but are postulated to be related to alterations in hormonal and cytokine profiles as well as changes in DNA methylation. Shifts in kidney function and cellular transport proteins are also critical to pharmacokinetics, but the significance of these changes to processing pharmaceuticals in space has yet to be determined. The assessment of pharmacodynamics in space has been minimal and largely inconclusive, so further studies need to be done to evaluate drug potency in space.

Additional concerns include altered bacterial virulence and chemical instability and degradation of medications aboard spacecraft. Compounded with the alterations in immune function that occur in astronauts, failure of antibiotic agents could be catastrophic for crewmembers. Conversely, upregulated immune activity may cause hypersensitivity reactions to medications. Lastly, it is important to note that many common medications can prolong cardiac QTc intervals (which increases risk for sudden cardiac death), so the fact that some studies showed that long-duration spaceflight increased QTc times is also concerning.

Engineering therapeutics for human space exploration

As we gain more molecular data on human response to spaceflight, we will be able to further tailor specific therapies and identify necessary medications to limit potential complications during long duration, deep space missions where resupplying will not be an option. From previous work we already knew the effects of spaceflight on bone and muscle atrophy, ocular changes, and cardiac changes. From the Twin Study we now have a molecular level understanding of drastic inflammation and cytokine responses during flight and upon re-entry. As this type of study is expanded to a larger population, we will begin to identify additional changes within specific individuals and astronauts in general. It may also open up means of genetic engineering for cells, of which many more options exist today than ever before.

The USA launched the first genetically engineered clinical trial in 1989, and many other countries have since begun various genetically engineered trials. From this came the invention of chimeric antigen receptors (CARs), which may persist long-term within patients. The first two FDA-approved CAR T-cell (CAR-T) therapies (Axicabtagene Ciloleucel and Tisagenlecleucel) were announced within the last few years. To create CAR-T therapies, T-cells are extracted from the patient or a donor, genetically engineered, expanded, and then infused into the patient to infiltrate any tissue system other T-cells can access to specifically target cells based on their single chain variable fragment.

Given the recent rise in genetic engineering and cellular therapeutic trials, future astronauts may be given cellular preventative or therapies to improve response to spaceflight and help ameliorate known hazards. One such example would be to engineer cells to have superior radiation-resistance abilities. Thankfully, Earth is full of diverse life forms with highly specialized and unique abilities so we are not forced to completely re-invent the wheel when it comes to trying to improve human response to new environments. Given that the main negative effect from radiation is directed towards DNA damage, it may make sense that improved DNA protection allows for cellular survivability and escapes from radiation-induced health consequences.

As such, research has been conducted into these radiation-tolerant mechanisms. Dsup, a protein found in tardigrades (an organism known for its radio-resistant abilities compared to humans) which has been shown to enhance DNA protection, is one potential candidate to improve overall human radiation-resistance. As a proof of concept, it has been shown that expression of Dsup within human cell lines improves their overall radiation-resistance when exposed to 1 Gy of irradiation.

Beyond this, other animals exist with superior anti-tumor effects. As an example, consider elephants which are much larger than the average human, and so containing many more cells, and further are likely to be exposed to more UV radiation. However, even given these characteristics which may otherwise increase susceptibility to cancer, elephants have a lower incidence of cancer relative to humans. Research has identified one potential reason for the decreased risk of cancer in elephants—20 copies (10 times more than an average human) of the prominent tumor-suppressor gene TP53.

Given the decrease incidence of cancer, it may make sense to increase the overall copy number of TP53 within human cells, as long as the expression is controlled and stable, especially if the person is expected to be exposed to a large amount of radiation.

Although these two examples would be best if applied to all cells within the body, a safer and likely more realist intervention would be to engineer the immune system directly. As an example, in a breakthrough concept paper in Cell, a group of researchers were able to identify a target which is ubiquitously expressed on differentiated myeloid cells, including cancerous acute myeloid leukemia (AML) cells, which is not essential for the development of these cell types, CD33. CD33 is already targeted within CAR clinical trials; however, side effects are likely unpreventable without this type of normal-tissue engineering before treatment.

Further engineering could be conducted to allow for immune-protected cells which are capable of secreting
necessary molecules to improve or stabilize humans during spaceflight. For example, regenerative medicine for diabetes involves the differentiation of cells into islets using either donor cells, such as embryonic stem cells (ESCs), or patient cells, such as induced pluripotent stem cells (iPSCs). These therapies then act as if they were the patient’s pancreas, capable of producing insulin in response to glucose. These therapies can further engrave to the patients in such a way that they are immune-privileged, where the encapsulation device does not allow for immune cell infiltration, or have direct engraftment and engagement with the host immune system. Such a paradigm would allow for a singular treatment every few months, or potentially years, as opposed to daily insulin dependency. If proven successful, this methodology could theoretically be applied to safely implant any engineered cell to aid in immune response, metabolism, or secretion of specific molecules in response to a stimulus or constitutively.

Taken together, these unique adaptations along with others could be combined to improve overall human health, response to spaceflight, and even response to specific hazards of space. The first introduction of these ideas will likely be through engineering the hematopoietic system. As an example, an astronaut’s own HSCs can be immobilized through injection of Granulocyte-colony stimulation factor (G-CSF). These cells can further be engineered to express Dsup, incorporate multiple copies of TP53, and even introduce specific variants within EPAS1. Together, this may allow for an overall increase in radio-resistance, decreased susceptibility to blood cancers, and decreased need for oxygen. These and other improvements should be applied to all tissue systems, or, ideally, specific tissue systems other than hematopoietic, as such specific modification would be less invasive and capable of high-quality control in vitro measurements before cells were re-infused. Of course, extensive pre-clinical models (mouse, primate) will need to be explored within these contexts to ensure their efficacy and safety. It may not be far-fetched to imagine a world where, once improved genetic engineering technologies have been developed, in vivo somatic engineering could also then take place.

Precision medicine could also be vital for measuring and maximizing efficacy of medications in astronauts. Minimally invasive tests, such as those utilizing liquid biopsies, would be fundamental for personalized omics studies regarding pharmaceutical agents. Expression of hepatic cytochrome p450 enzymes, cellular transport proteins, hormonal and cytokine profiles, DNA methylation analysis, and microbiome genomics and metabolomics can all be directly applied to tailoring effective medical treatment for humans in space.

Finally, microbiome therapies are also a key component of the astronaut’s health, the general environment, and also could be customized to ensure continued diversity and overall function. While ratios of the Firmicutes and Bacteroidetes changed in a potentially negative direction in the Twin Study, they did revert back to normal upon return to Earth. In future studies, probiotics could be administered to prevent this shift, and continuous monitoring of the microbiome of the astronauts could optimize this approach. Notably, it has already been shown that DNA sequencing can reliably function in microgravity, enabling sequencing on the ISS as well as detection of modified nucleic acids in the microbes on the ISS, meaning the technology is also in place for continual precision metagenomics for the astronauts.

Conclusions

The effects of spaceflight on the human body extend from physiological changes at the level of tissue structure and fluid compartments, down to molecular alterations in DNA, RNA, and protein. The NASA Twin Study has given us a detailed look at the omics of spaceflight and shed light on some of the most important shifts that can occur, yet there is still much left to learn. Additional studies will be required to extrapolate the data, develop cutoffs, create quantitative guidelines, and shape algorithms for flight surgeons to monitor and intervene when necessary. In the near future we will likely begin to see new cellular therapy paradigms which exist in the clinic to be applied to astronauts to help combat the hazards of spaceflight and further missions away from Earth. Furthermore, new assays and metrics of health and disease will invariably emerge that we cannot predict today. Thus, having viably frozen cells and fluids will be essential to future-proof the collection protocols as much as possible. Moreover, the expansive, recent work on cell-free DNA and RNA metrics that can serve as a “molecular whole body scan” also show great promise, indicating that care in storing and preserving all samples will be beneficial to future astronauts in space as well as patients here on Earth.

Precision medicine will be vital for measuring and maximizing efficacy of medications in astronauts. Expression of hepatic cytochrome p450 enzymes, cellular transport proteins, hormonal and cytokine profiles, DNA methylation analysis, and microbiome genomics and metabolomics can all be directly applied to tailoring effective medical treatment for humans in space. Further, sequencing in space, as shown with Oxford Nanopore, can empower astronauts with immediate and actionable data in regard to their own health or experiments being conducted. Further preventative treatments and enhancements may be possible in the near future through the use of cellular engineering therapeutics. As more genetically engineered therapies are approved by the FDA and more long-term studies have been completed, we will likely begin to apply these...
types of paradigms to address newly found spaceflight hazards and complications.

Acknowledgments

We would like to thank the Epigenomics Core Facility at Weill Cornell Medicine, the Scientific Computing Unit (SCU), as well as the Starr Cancer Consortium (I9-A9-071) and funding from the Irma T. Hirsch and Monique Weill–Caulier Charitable Trusts, Bert L and N Kuggie Vallee Foundation, the WorldQuant Foundation, the Pershing Square Sohn Cancer Research Alliance, NASA (Grants No. NNX14AH50G, NNX17AB26G), the National Institutes of Health (Grants No. R25EB020393, R01NS076465, R01AI125416, R01ES021006, 1R21AI129851, P01HD067244, 1R01MH117406), TRISH (Grants No. NNX16AO69A:0107, NNX16AO69A:0061), the Bill and Melinda Gates Foundation (Grants No. OPP1151054), the Leukemia and Lymphoma Society (LLS) grants (No. LLS 9238–16, Mak, No. LLS–MCL–982, Chen–Kiang) and the NSF (Grants No. 1840275), the Alfred P. Sloan Foundation (Grants No. G-2015-13964). We thank Francine Garrett-Bakelman for her comments on the study and development of the protocols.

Conflict of interest statement

None declared.

References

1. Levin SG, Young RW, Stohler RL. Estimation of median human lethal radiation dose computed from data on occupants of reinforced concrete structures in Nagasaki, Japan. Health Phys 1992;63:522–31. doi: 10.1097/00004032-199211000-00003.
2. Elgart SR, Little MP, Chappell LJ, et al. Radiation exposure and mortality from Cardiovascular Disease and Cancer in early NASA Astronauts. Sci Rep 2018;8:8480. doi: 10.1038/s41598-018-25467-9.
3. Boice JD Jr. Space: The final frontier-research and mortality from Cardiovascular Disease and Cancer in early NASA Astronauts. Sci Rep 2018;8:8480. doi: 10.1038/s41598-018-25467-9.
4. Elgart SR, Little MP, Chappell LJ, et al. Radiation exposure and mortality from Cardiovascular Disease and Cancer in early NASA Astronauts. Sci Rep 2018;8:8480. doi: 10.1038/s41598-018-25467-9.
5. Brzozovskiy A, Kononikhin A, Indeykina M, et al. Label-free study of cosmonaut's urinary proteome changes after one year-long human spaceflight. Exp Gerontol 2020;137:111072. doi: 10.1016/j.exger.2020.111072.
6. Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013;368:987–98. doi: 10.1056/NEJMoa1209825.
7. Little MP, Azizova TV, Bazyka D, et al. Systematic review and meta-analysis of circulatory disease from exposure to low-level ionizing radiation and estimates of potential population mortality risks. Environ Health Perspect 2012;120:1503-11. doi: 10.1289/ehp.1204982.
8. Little MP. Radiation and circulatory disease. Mutat Res 2016;770(Part B):299–318. doi: 10.1016/j.mrrev.2016.07.008.
9. Stewart FA, Akleyev AV, Hauer-Jensen M, et al. ICRP publication 118: ICRP statement on tissue reactions and early and late effects of radiation in normal tissues and organs–threshold doses for tissue reactions in a radiation protection context. Ann ICRP 2012;41:1–322. doi: 10.1016/j.icrp.2012.02.001.
10. Garrett-Bakelman FE, Darsh M, Green SJ, et al. The NASA twins study: a multi-dimensional analysis of a year-long human spaceflight. Science 2019;364. doi: 10.1126/science.aau8650.
11. Alizadeh A, Aranda V, Bardelli A, et al. Toward understanding and exploiting tumor heterogeneity. Nat Med 2015;21:846–53. doi: 10.1038/nm.3915.
12. Almeida-Portada G, Rodman C, Kuhlman B, et al. Exposure of the bone marrow microenvironment to simulated solar and galactic cosmic radiation induces biological bystander effects on human hematopoiesis. Stem Cells Dev 2018;27:1237–56. doi: 10.1089/scd.2018.0005.
13. Rodman C, Almeida-Portada G, George SK, et al. In vitro and in vivo assessment of direct effects of simulated solar and galactic cosmic radiation on human hematopoietic stem/progenitor cells. Leukemia 2017;31:1398–407. doi: 10.1038/leu.2016.344.
14. Crucian BE, Choukr A, Simpson RJ, et al. Immune system Dysregulation during spaceflight: potential countermeasures for deep space exploration missions. Front Immunol 2018;9:1437. doi: 10.3389/fimmu.2018.01437.
15. Cogoli A, Tschopp A, Fuchs-Bislin P. Cell sensitivity to gravity. Science 1994;265:228–30. doi: 10.1126/science.7679481.
16. Desai P, Mencia-Trinchant N, Savenkov O, et al. Somatic mutations precede acute myeloid leukemia years before diagnosis. Nat Med 2018;24:1015–23. doi: 10.1038/s41591-018-0081-z.
17. Busque L, Patel J, Figueroa ME, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet 2012;44:1179–81. doi: 10.1038/ng.2413.
18. Lalani R, Bhasin S, Byhower F, et al. Myostatin and insulin-like growth factor-I and -II expression in the musculoskeletal system of rats exposed to the microgravity environment of the NeuroLab space shuttle flight. J Endocrinol 2000;167:417–28.
19. Barreres R, Osler ME, Yan J, et al. Non-CpG methylation of the PGC-1α promoter through DNMT3B controls mitochondrial density. Cell Metab 2009;10:189–98. doi: 10.1016/j.cmet.2009.07.011.
20. Scarpulla RC. Metabolic control of mitochondrial biogenesis through the PGC-1α promoter. Cell Metab 2009;10:189–98. doi: 10.1016/j.cmet.2009.07.011.
21. Pastushkova LH, Dobrokhotov IV, Veselova OM, et al. Identification and function of microRNAs in the immune network. Biochim Biophys Acta 2011;1813:1269–78. doi: 10.1016/j.bbamcr.2010.09.019.
22. Stein TP, Leskiw MJ, Schluter MD. Diet and nitrogen metabolism during spaceflight on the shuttle. J Appl Physiol 1996;81:82–97. doi: 10.1152/jappl.1996.81.1.82.
23. Nabavi N, Khondani A, Camirand A, et al. Effects of microgravity on osteoblast cytoskeletal organization and adhesion. Bone 2011;49:965–74. doi: 10.1016/j.bone.2011.07.036.
24. De la Torre GG. Cognitive neuroscience in space. Life (Basel, Switzerland) 2014;4:281–94. doi: 10.3390/life4030281.
25. Wotring V, Smith L. Dose Tracker: an iOS app for collection of medication use data from volunteer crewmembers on the International Space Station. Frontiers in Physiology. http://www.frontiersin.org/journal/FullText.aspx?id=65&name=physiology&ART_ID=10.3389/conf.physiospace.2018.26.00047.

26. Pavy-Le Traon A, Saivin S, Souleiz-LaRiviere C, et al. Pharmacology in space: pharmacotherapy. Adv Space Biol Med 1997;6:93–105. doi: 10.1169/1569-2574(08)060079-9.

27. Barger LK, Flynn-Evans EE, Kubey A, et al. Prevalence of sleep deficiency and use of hypnotic drugs in astronauts before, during, and after spaceflight: An observational study. Lancet Neurol 2014;13:904–12. doi: 10.1016/S1474-4223(14)70122-X.

28. Putcha L, Berens KL, Marshburn TH, et al. Pharmaceutical use by U.S. astronauts on space shuttle missions. Aviat Space Environ Med 1999;70:705–8. PMID: 10417009.

29. Wotring VE. Medication use by U.S. crewmembers on the international space station. FASEB J 2015;29:4417–23. doi: 10.1096/fj.14-264838.

30. Calhoun SF, Reed J, Alexander N, et al. "Chromosome end repair and genome stability in plasmid falciparum." mBio 2017;8:pii: e00547–17. doi: 10.1128/mBio.00547-17.

31. Leblanc A, Matsumoto T, Jones J, et al. Bisphosphonates as a supplement to exercise to protect bone during long-duration spaceflight. Osteoporos Int 2013;24:2105–14. doi: 10.1007/s00198-012-2243-z.

32. Murad M. Contraception in the cosmos: the combined oral contraceptive pill in space. J Fam Plan Reprod Health Care 2004;30:55–9. doi: 10.1208/s12248-011-9270-0.

33. Wotring VE. Evidence report: risk of therapeutic failure due to ineffectiveness of medication. National Aeronautics and Space Administration, Lyndon B. Johnson Space Center, Houston, Texas; 2011 Available at: https://humanresearchroadmap.nasa.gov/evidence/reports/pharm.pdf.

34. Eyal S, Hsiao P, Unadkat JD. Drug interactions at the brain barrier and the impact of breast cancer resistance protein (ABCG2). Brain Pharm Res 2015;40:2680–85. doi: 10.1007/s12248-015-9345-5.

35. Eyal S, Derendorf H. Medications in space: in search of a pharmacologist’s guide to the galaxy. Pharm Res 2019;36:148. doi: 10.1007/s11095-019-2679-3.

36. Aunins TR, Erickson KE, Prasad N, et al. Spaceflight modifies Escherichia coli gene expression in response to antibiotic exposure and reveals role of oxidative stress response. Front Microbiol 2018;9:310. doi: 10.3389/fmicb.2018.00310.

37. Verbandt Y, Wantier M, et al. Spaceflight alters bacterial gene expression and virulence and reveals a role for global regulator Hfq. Proc Natl Acad Sci U S A 2007;104:16299–304. doi: 10.1073/pnas.0707155104.

38. Wotring VE. Chemical potency and degradation products of medications stored over 550 earth days at the international space station. Aviat Space Environ Med 1985;56:748–51. PMID: 3899095.

39. Wilson IF, Ott CM, Honer Z, et al. Spaceflight alters bacterial gene expression and virulence and reveals a role for global regulator Hfq. Proc Natl Acad Sci U S A 2007;104:16299–304. doi: 10.1073/pnas.0707155104.

40. Wotring VE. Medication use by U.S. crewmembers on the international space station. FASEB J 2015;29:4417–23. doi: 10.1096/fj.14-264838.

41. Rowland M, Tozer TN. Clinical pharmacokinetics - concepts and applications, 3rd edn. Media, PA: Williams & Wilkins, 1995.

42. Putcha L, Berens KL, Marshburn TH, et al. Pharmaceutical use by U.S. astronauts on space shuttle missions. Aviat Space Environ Med 1999;70:705–8. PMID: 10417009.

43. Grigoriev AI, Bugrov SA, Bogomolov VV, et al. Preliminary medical results of the Mir year-long mission. Acta Astronaut 1991;23:1–8. doi: 10.1016/0092-6985(91)90092-j.

44. Putcha L, Kovachevich I. Physiologic Alterations and Pharmacokinetic Changes During Space Flight (2.3.1). Available at: https://lsda.jsc.nasa.gov/Experiment/expere/359.

45. Engel G, Hofmann U, Heidemann H, et al. Antipyrine as a probe for human oxidative drug metabolism: Identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Clin Pharmacol Ther 1996;59:613–23. doi: 10.1001/s0009-2926(96)00001-6.

46. Eyal S, Derendorf H. Medications in space: in search of a Pharmacologist’s guide to the galaxy. Pharm Res 2019;36:148. doi: 10.1007/s11095-019-2679-3.

47. Aunins TR, Erickson KE, Prasad N, et al. Spaceflight modifies Escherichia coli gene expression in response to antibiotic exposure and reveals role of oxidative stress response. Front Microbiol 2018;9:310. doi: 10.3389/fmicb.2018.00310.

48. Tixador R, Richolley G, Gasset G, et al. Study of minimal inhibitory concentration of antibiotics on bacteria cultivated in vitro in space (Cytos 2 experiment). Aviat Space Environ Med 1985;56:748–51. PMID: 3899095.

49. Wilson IF, Ott CM, Honer Z, et al. Spaceflight alters bacterial gene expression and virulence and reveals a role for global regulator Hfq. Proc Natl Acad Sci U S A 2007;104:16299–304. doi: 10.1073/pnas.0707155104.

50. Bogomolov VV, Kondratenko SN, Kovachevich IV. Testing stability of tableted acetaminophen and furosemide after 6-month storage in space flight. Aviat Space Environ Med 2015;49:12–5. PMID: 26087581.

51. Du B, Daniels VR, Vaksman Z, et al. Evaluation of physical and chemical changes in pharmaceuticals flown on space missions. AAPS J 2011;13:299–308. doi: 10.1208/s12248-011-9270-0.

52. Wotring VE. Chemical potency and degradation products of medications stored over 550 earth days at the international space station. AAPS J 2016;18:210–6. doi: 10.1208/s12248-015-9834-5.

53. Eyal S, Derendorf H. Medications in space: i search of a pharmacologist’s guide to the galaxy. Pharm Res 2019;36:148. doi: 10.1007/s11095-019-2679-3.

54. Blue RS, Bayuse TM, Daniels VR, et al. Supplying a pharmacy for NASA exploration spaceflight: challenges and current understanding. NPJ Microgravity 2019;5:14. doi: 10.1038/s41526-019-0075-2.

55. D’Aunno DS, Dougherty AH, DeBlock HF, et al. Effect of short- and long-duration spaceflight on QTc intervals in healthy astronauts. Am J Cardiol 2003;91:494–7. doi: 10.1016/s0002-9149(02)03259-9.

56. Ginn SL, Amaya AK, Alexander IE, et al. Gene therapy clinical trials worldwide to 2017: an update. J Gene Med 2018;20:e3015. doi: 10.1002/jgm.3015.

57. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 2017;377:2531–44.

58. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-Cell Lymphoblastic Leukemia. N Engl J Med 2018;378:439–48. doi: 10.1056/NEJ-Moa1709866.
59. Hashimoto T, Horikawa DD, Saito Y, et al. Extremotolerant tardigrade genome and improved radiotolerance of human cultured cells by tardigrade-unique protein. Nat Commun 2016;7:12808. doi: 10.1038/ncomms12808.

60. Sulak M, Fong L, Mika K, et al. TP53 copy number expansion is associated with the evolution of increased body size and an enhanced DNA damage response in elephants. Elife 2016;5. pii: e11994. doi: 10.7554/eLife.11994.

61. Kim MY, Yu K-R, Kenderian SS, et al. Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia. Cell 2018;173:1439–1453.e19. doi: 10.1016/j.cell.2018.05.013.

62. MacKay M, Afshinnekoo E, Rub J, et al. The target landscape for cells engineered with chimeric antigen receptors. Nat Biotechnol in press.

63. Dadheech N, James Shapiro AJ. Human induced pluripotent stem cells in the curative treatment of diabetes and potential impediments ahead. Adv Exp Med Biol 2019;1144:25–35. doi: 10.1007/5584_2018_305.

64. Voorhies AA, Ott CM, Mehta S, et al. Study of the impact of long-duration space missions at the international space station on the astronaut microbiome. Sci Rep 2019;9:9911. doi: 10.1038/s41598-019-46303-8.

65. The MetaSUB International Consortium. The Metagenomics and Metadesign of the subways and urban biomes (MetaSUB) international consortium inaugural meeting report. Microbiome 2016;4:24. https://doi.org/10.1186/s40168-016-0168-z.

66. McIntyre ABR, Rizzardi L, Yu AM, et al. Nanopore sequencing in microgravity. NPJ Microgravity 2016;2:16035. doi:10.1038/npjmgrav.2016.35.

67. Castro-Wallace SL, Chiu CY, John KK, et al. Nanopore DNA sequencing and genome assembly on the international space station. Sci Data 2017;7:18022. doi: 10.1038/s41598-017-18364-0.

68. McIntyre ABR, Alexander N, Grigorev K, et al. Single-molecule sequencing detection of N6-methyladenine in microbial reference materials. Nat Comm 2019;10:579. doi: 10.1038/s41467-019-08289-9.

69. Afshinnekoo E, Chou C, Alexander N, et al. Precision metagenomics: rapid metagenomic analyses for infectious disease diagnostics and public health surveillance. J Biomol Tech 2017;28:40–5. doi: 10.7171/jbt.17-2801-007.